The human Müllerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer: Validation using the mAb 12G4

Ovarian cancer has the highest mortality rate among gynecologic malignancies. The monoclonal antibody 12G4 specifically recognizes the human Müllerian inhibiting substance type II receptor (MISRII) that is strongly expressed in human granulosa cell tumors (GCT) and in the majority of human epithelia...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:MAbs
Main Authors: Kersual, Nathalie, Garambois, Véronique, Chardès, Thierry, Pouget, Jean-Pierre, Salhi, Imed, Bascoul-Mollevi, Caroline, Bibeau, Frédéric, Busson, Muriel, Vié, Henri, Clémenceau, Béatrice, Behrens, Christian K, Estupina, Pauline, Pèlegrin, André, Navarro-Teulon, Isabelle
Format: Artigo
Jezik:Inglês
Izdano: Taylor & Francis 2014
Teme:
Reports
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4623115/
https://ncbi.nlm.nih.gov/pubmed/25517316
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/mabs.29316
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki